Int J Cancer. 2011 Mar 1;128(5):1120-8.
Long term follow up of patients with resected pancreatic cancer following vaccination against mutant K-RAS.
J. Mol. Med., 2003, 81(1): 43-50.
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T helper epitopes. View abstract
Int.J.Cancer, 2001, 92, 441-450, 2001
Intradermal RAS peptide vaccination with Granulocyte-Macrophage Colony-Stimulating Factor as adjvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.
Int.J.Cancer, 1997: 72, 784–790.
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognise 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Brit. J.Cancer, 1996, 74: 1828-1833.
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study. View abstract
Lancet. 1995 Nov 25;346(8987):1399-400.
Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. View abstract
Int. J. Cancer. 1994, 56: 40-45.
p21-RAS-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T-cells recognise a peptide corresponding to a common mutation (13Gly-->Asp). View abstract
Eur. J. Immunol. 1993, 23: 2687-2691.
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 RAS can be recognised by HLA-DR, -DP and -DQ restricted T-cells. View abstract
Eur.J.Immunol. 1993, 23; 754-760
T-cell clones specific for p21 ras derived peptides: characterisation of their fine specificity and HLA restriction. View abstract
Hum. Immunol. 33, 1992, 266-274.
T-cell responses against products of oncogenes: generation and characterisation of human T-cell clones specific for p21 RAS-derived synthetic peptides. View abstract